A series of
N
-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles was synthesised and screened for their potential to inhibit kinases and exhibit anticancer activity against primary patient-derived glioblastoma 2D cells and 3D neurospheres. A collection of 10 compounds was evaluated against glioma cell lines, with compound
4j
exhibiting promising glioma growth inhibitory properties. Compound
4j
was screened against 139 purified kinases and exhibited low micromolar activity against kinase AKT2/PKBβ. AKT signalling is one of the main oncogenic pathways in glioma and is often targeted for novel therapeutics. Indeed, AKT2 levels correlated with glioma malignancy and poorer patient survival. Compound
4j
inhibited the 3D neurosphere formation in primary patient-derived glioma stem cells and exhibited potent EC
50
against glioblastoma cell lines. Although exhibiting potency against glioma cells,
4j
exhibited significantly less cytotoxicity against non-cancerous cells even at fourfold–fivefold the concentration. Herein we establish a novel biochemical kinase inhibitory function for
N
-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles and further report their anti-glioma activity
in vitro
for the first time.
KEY MESSAGE
Anti-glioma pyrano[2,3-c]pyrazole
4j
inhibited the 3D neurosphere formation in primary patient-derived glioma stem cells.
4j
also displayed PKBβ/AKT2 inhibitory activity.
4j
is nontoxic towards non-cancerous cells.